Rowlandmiller & PARTNERS.ADV Reduces Stock Holdings in Zoetis Inc. (NYSE:ZTS)

Rowlandmiller & PARTNERS.ADV decreased its position in Zoetis Inc. (NYSE:ZTS) by 4.3% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,653 shares of the company’s stock after selling 120 shares during the period. Rowlandmiller & PARTNERS.ADV’s holdings in Zoetis were worth $518,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of the company. Webster Bank N. A. lifted its position in shares of Zoetis by 89.1% during the first quarter. Webster Bank N. A. now owns 174 shares of the company’s stock worth $29,000 after acquiring an additional 82 shares in the last quarter. Quarry LP lifted its position in shares of Zoetis by 273.2% during the second quarter. Quarry LP now owns 209 shares of the company’s stock worth $36,000 after acquiring an additional 153 shares in the last quarter. LRI Investments LLC purchased a new stake in shares of Zoetis during the first quarter worth $43,000. Central Valley Advisors LLC purchased a new stake in shares of Zoetis during the second quarter worth $49,000. Finally, Future Financial Wealth Managment LLC purchased a new stake in shares of Zoetis during the first quarter worth $51,000. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Analyst Ratings Changes

Several research firms recently issued reports on ZTS. Stifel Nicolaus lifted their price objective on Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a research note on Wednesday, September 18th. JPMorgan Chase & Co. lifted their price objective on Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a research note on Friday, October 11th. Piper Sandler lifted their price objective on Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a research note on Wednesday, August 14th. Argus upgraded Zoetis to a “strong-buy” rating in a research report on Friday, August 9th. Finally, BTIG Research raised their price target on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research report on Monday, August 12th. Ten research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $221.44.

Zoetis Stock Performance

Zoetis stock opened at $181.52 on Friday. The stock’s 50 day simple moving average is $189.23 and its two-hundred day simple moving average is $177.58. The company has a debt-to-equity ratio of 1.32, a quick ratio of 2.09 and a current ratio of 3.45. The stock has a market cap of $82.24 billion, a price-to-earnings ratio of 35.52, a PEG ratio of 2.94 and a beta of 0.89. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $201.92.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $1.56 earnings per share for the quarter, beating the consensus estimate of $1.49 by $0.07. Zoetis had a return on equity of 50.67% and a net margin of 26.29%. The business had revenue of $2.36 billion for the quarter, compared to analysts’ expectations of $2.31 billion. During the same period in the previous year, the firm posted $1.41 EPS. The business’s revenue was up 8.3% on a year-over-year basis. As a group, analysts expect that Zoetis Inc. will post 5.83 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 3rd. Stockholders of record on Thursday, October 31st will be given a $0.432 dividend. The ex-dividend date is Thursday, October 31st. This represents a $1.73 dividend on an annualized basis and a dividend yield of 0.95%. Zoetis’s dividend payout ratio is currently 33.86%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.